Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-668,402
Closed -$13.6M 708
2023
Q3
$13.6M Sell
668,402
-3,690
-0.5% -$92.8K 0.1% 191
2023
Q2
$19.6M Buy
672,092
+39,669
+6% +$1.09M 0.14% 162
2023
Q1
$16.4M Buy
632,423
+5,845
+0.9% +$150K 0.11% 193
2022
Q4
$11.6M Sell
626,578
-539
-0.1% -$9.23K 0.08% 242
2022
Q3
$9.88M Buy
627,117
+3,844
+0.6% +$86.3K 0.07% 275
2022
Q2
$15.7M Buy
623,273
+210,155
+51% +$6.29M 0.13% 170
2022
Q1
$14.9M Buy
413,118
+132,070
+47% +$6.5M 0.1% 204
2021
Q4
$21.5M Buy
281,048
+53,520
+24% +$4.72M 0.14% 168
2021
Q3
$21.9M Buy
227,528
+46,928
+26% +$5.12M 0.15% 160
2021
Q2
$19.3M Buy
+180,600
New +$17.8M 0.13% 183

Other funds holding CRNC

Candriam SCA's CRNC Position: Q4 2023 in Review

Candriam SCA sold out of Cerence (CRNC) in Q4 2023, closing a stake of 668,402 shares — an estimated $13.6M sold.

Candriam SCA first reported a position in CRNC in Q2 2021 and held it in 10 quarters. The position peaked at $21.9M in Q3 2021. 217 funds tracked by Wall St. Rank hold CRNC as of Q4 2023.

  • Candriam SCA reported no remaining Cerence position as of Q4 2023 after selling out during the quarter.
  • Candriam SCA sold 668,402 Cerence shares in Q4 2023, an estimated $13.6M.
  • Candriam SCA first reported a position in Cerence in Q2 2021 and held it in 10 quarters.
  • Candriam SCA's Cerence position peaked at $21.9M in Q3 2021.
  • 217 funds tracked by Wall St. Rank held Cerence as of Q4 2023.

Based on Candriam SCA's 13F filing for Q4 2023, filed 14 Feb 2024.